Navigation Links
Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
Date:9/18/2009

SAN FRANCISCO, Sept. 18 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

As previously reported, the net proceeds of the private placement will be used to continue advancing the Company's clinical development programs with the lead product JX-594. Key value creating milestones planned for the next 12 months include completion of a randomized Phase II trial in liver cancer, followed by initiation of a pivotal Phase III trial in liver cancer. In addition, Jennerex plans to complete a Phase I trial in solid cancers (including lung and colorectal), followed by initiation of a Phase II colorectal cancer trial. Proceeds will also be used for manufacturing, general corporate purposes and to augment working capital.

"This Series C was a success due both to continued investment from many of our current Shareholders, as well as support from a number of important new investors. We are particularly pleased to welcome the Ottawa Regional Cancer Foundation as a significant new investor," said David H. Kirn, M.D., President and CEO. "Jennerex and the Foundation share a common vision of extending and preserving the lives of patients with cancer. We also share a common commitment to build on the great strength of biological research and world-class facilities at the Ottawa Hospital Research Institute (OHRI). The Cancer Foundation's participation will further support and extend the scope of joint research and development activities being undertaken in partnership with Jennerex at the OHRI, including expansion of manufacturing and clinical trial activities," said Dr. Kirn.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Closes $5 Million First Tranche of Series C Financing
2. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
5. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
6. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
7. EAU Completes Approval Process for Electrolyzed Water as Sanitation Process for Industrial Clean-in-Place Application
8. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
9. ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development
10. Pacific Biometrics Completes $4 Million Debt Financing
11. Alexza Stockholders Approve Share Issuance to Symphony Capital and Alexza Completes Acquisition of Symphony Allegro
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... College, MIT, Clemson and Virginia have used nanotechnology to ... of merit of p-type half-Heusler, a common bulk semiconductor ... journal Nano Letters . The dramatic increase ... material,s relative thermoelectric performance, could pave the way for ...
... RxTrials, Inc., a network of premier clinical research ... national clinical research consultant and education provider, has earned ... certification was presented by the Women,s Business Enterprise National ... visit. The nationally recognized certification from WBENC ...
... that a new market research report is available ... of In Vitro and In Vivo Diagnostic Integration ... The term in-vitro/in-vivo diagnostics (IV2D) describes the integration ... as well as new software and IT platforms. ...
Cached Biology Technology:Nanotech milling produces dramatic increase in thermoelectric performance of bulk semiconductor 2RxTrials Earns National Women-Owned Business Certification 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 3
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... evidence has demonstrated that transplantation of mesenchymal stem cells ... or mouse models of Alzheimer,s disease (AD) and improve ... ischemia. Few studies are reported on the therapeutic effect ... AD and on the effect on oxidative injury and ... Yan and her team, School of Life Sciences, Tsinghua ...
(Date:7/11/2014)... the proteins that let nerve cells send out electrical ... a biological tactic that may offer a new way ... and environmentally responsible way. , Their findingthat naturally ... and harmless for a closely related onesuggests that insecticides ... beneficial species like bees. A summary of the research, ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... Mich. --- Tiny creatures at the bottom of the ... of the atmosphere,s carbon dioxide, yet research by Michigan ... to "sequester" that greenhouse gas as the climate warms. ... living in puddles, lakes and oceans. ...
... Alexandria, Va. The International Association for Dental ... Tufts,University, Boston, Massachusetts, USA, as the 2009 recipient ... presented at the IADR 87th General Session & ... 2009,Dr. Papas is the Erling Johansen Professor of ...
... developed by the UK,s National Oceanography Centre, Southampton, has ... under an Antarctic glacier. Autosub has been exploring ... Antarctic ice sheet, using sonar scanners to map the ... juts into the sea. Scientists hope to learn why ...
Cached Biology News:Mighty diatoms: Global climate feedback from microscopic algae 2Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award 2UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity 2UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity 3
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
... (phospho Y1007) ( Abpromise for ... Antigen: Synthesized phosphopeptide derived from ... of tyrosine 1007 (K-E-Y P -Y-K). ... 3717 Swiss ...
Harmful, Irritant, Combustible ,DEPC...
Permeabilization Solution, 5X...
Biology Products: